Latest Conference Articles

Assessing the Impact of Radiology Workforce Shortages in Rural Communities

In an interview at the recent RSNA conference, Catherine Everett, M.D., shared her perspective on the radiology workforce shortage, offered insights on recruiting radiologists to rural areas and emphasized the urgency of bolstering access to radiologists and other health-care professionals for at-risk communities.

Can AI Improve Detection of Extraprostatic Extension on MRI?

Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10 percent higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the recent RSNA conference.

Emerging PSMA PET Agent May Offer Improved Detection of Prostate Cancer

The PSMA PET agent 64Cu SAR-bisPSMA detected a higher number of prostate cancer lesions and had a significantly higher SUVmax and SUVmean than 68Ga PSMA-11 PET/CT, according to initial data from a prospective multisite study presented at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference.

Emerging Innovations in Molecular Imaging

In interviews at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, researchers discussed the potential impact of ultra-high resolution brain positron emission tomography (PET) as well as emerging PET radiotracers for detecting coronary artery disease in obese patients and diagnosing clear cell renal cell carcinoma.

Can an Emerging PET Radiotracer Be a Viable Alternative to Multiparametric MRI for Detecting Prostate Cancer Recurrence?

In an analysis of patients with intraprostatic/prostate bed findings of biochemical prostate cancer recurrence, the use of 18F-DCFPyL PET/CT led to an 82.3 percent cancer detection rate in comparison to 80 percent for multiparametric MRI, according to research presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.

In a video interview, Hong Song, M.D., Ph.D., discussed retrospective research, presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, that evaluated the combination of artificial intelligence (AI)-based software and the PSMA agent piflufolastat F 18 to help quantify prostate cancer lesions and associations with biochemical progression-free survival.